FDA advisers raise doubts about experimental ALS drug

The advisory committee voted 6 to 4 that there was not enough evidence from the single clinical trial to conclude that Amylyx Pharmaceuticals’ drug works.


Not all news on the site expresses the point of view of the site, but we transmit this news automatically and translate it through programmatic technology on the site and not from a human editor.
Back to top button